This book is the first in a two-volume set that offers comprehensive guidance on the diagnosis of bone tumors based on the WHO classification as well as management and follow-up. The emphasis throughout is on an integrated approach to diagnosis that highlights the role of clinical, radiologic, and pathologic correlation in reducing the possibility of diagnostic errors. The diagnosis of bone tumors is difficult for a variety of reasons, including various tumor subtypings, the protean radiologic manifestations, the variable pathologic findings, the presence of reactive changes, and overlapping findings between benign and malignant tumors. The author's aim is to offer the reader the best possible guidance in negotiating these difficulties. For each tumor type, a wide range of cases are presented, from the common to the very rare. Appearances on the full range of imaging studies are illustrated, including conventional radiographs, bone scans, MRI, and PET CT scans. Attention is also drawn to the role of long-term follow-up radiographs in ensuring correct diagnosis and management. This book will be an ideal resource for all practitioners and researchers involved in bone tumor diagnosis and clinical management. Volume 1 covers chondrogenic, osteogenic, fibrogenic, fibrohistiocytic, hematopoietic, osteoclastic giant cell-rich, and notochordal tumors.
1. Chondrogenic tumors. A. Benign. a. Osteochondroma.- b. Chondroma ;
enchondroma, periostal chondroma .- c. Subungual exostosis.- d.- Bizzare
parosteal osteochondromatous proliferation.- e. Synovial chondromatosis.- B.
Intermediate (Locally aggressive).- a. Chondromyxoid fibroma.- b. Atypical
cartilaginous tumor/ Chondrosarcoma grade 1.- C. Intermediate (rarely
metastasizing).- a. Chondroblastoma.- D. Malignant.- a. Chondrosarcoma, grade
II/grade III.- b. Dedifferentiated chondrosarcoma.- c. Mesenchymal
chondrosarcoma.- d. Clear cell chondrosarcoma.-
2. Osteogenic tumors.- A.
Benign.- a. Osteoma.- b. Enostosis (bone island)/Osteopoikilosis.- c.
Melorhesotosis.- d. Osteoid osteoma.- B. Intermediate.- a. Osteoblastoma.- C.
Malignant.- a. Low-grade central osteosarcoma.- b. Conventional
osteosarcoma.- c. Giant cell rich osteosarcoma .- d. Telangiectatic
osteosarcoma.- e. Small cell osteosarcoma.- f. Secondary osteosarcoma.- g.
Parosteal osteosarcoma.- h. Periosteal osteosarcoma.- 3.Fibrogenic tumors.-
A. Intermediate (locally aggressive).- a. Desmoplastic fibroma of bone.- B.
Malignant .- a. Fibrosarcoma of bone.-
4. Fibrohistiocytic tumors.- A. Benign
fibrous hitiocytoma/Non-ossifying fibroma.-
5. Hematopoietic neoplasm.- A.
Malignant .- a. Plasma cell myeloma.- b. Solitary plasmacytoma of bone.- c.
Primary non-Hodgkin lymphoma of bone.-
6. Osteoclastic giant cell rich
tumors.- A. Benign.- a. Giant cell lesion of the small bones.- B.
Intermediate (locally aggressive, rarely metastasizing).- a. Giant cell tumor
of bone.- C. Malignant.- a. Malignancy in giant cell tumor of bone.-
7.
Notochordal tumors.- A. Benign.- a. Benign notochordal tumor.- B. Malignant.-
a. Chordoma.
Won-Jong Bahk, M.D., Professor, Department of Orthopaedic Surgery, Uijeongbu St. Mary Hospital, The Catholic University of Korea, Uijeongbu, South Korea.
